SCI TRANSL MED：广谱新药GS-5734可有效抵御冠状病毒

2017-06-30 cailingrui MedSci原创

GS-5734对病毒的预防性和早期治疗作用，显著降低了肺部病毒量，极大地改善了临床症状和呼吸机能。这些数据为GS-5734可以有效对抗中东呼吸综合征冠状病毒和人类冠状病毒提供了有力证据，更为抵御将来可能出现的新的冠状病毒起着重要作用。

新兴的病毒感染通常难以控制，因为异质性的病毒会周期性循环进出人类和动物宿主，使得具有针对性的抗病毒治疗和疫苗的研发变得极为复杂。冠状病毒(Coronaviruses, CoVs) 具有迅速在新宿主物种中传播并引起严重疾病的能力。严重急性呼吸系统综合征冠状病毒(SARS-CoV)和中东呼吸综合征冠状病毒(MERS-CoV)相继出现，导致严重的流行性呼吸疾病在全球迅速传播。能够抑制冠状病毒传染的广谱疗法将会立即解决医疗需求的缺口，在治疗新发的和地方性的冠状病毒感染中都将有着不可估量的价值。

研究结果显示，尚处于临床研发阶段用于治疗埃博拉病毒的核酸前体药物GS-5734，可以有效抑制体外培养环境中的SARS-CoV和MERS-CoV复制。GS-5734还可以有效对抗蝙蝠冠状病毒，流行性蝙蝠冠状病毒，主要在人类肺细胞中传播流行的人类冠状病毒等，都展示了其抗冠状病毒的光谱性。

在SARS-CoV发病机制的小鼠模型中，GS-5734对病毒的预防性和早期治疗作用，显著降低了肺部病毒量，极大地改善了临床症状和呼吸机能。这些数据为GS-5734可以有效对抗中东呼吸综合征冠状病毒和人类冠状病毒提供了有力证据，更为抵御将来可能出现的新的冠状病毒起着重要作用。

原始出处：

Timothy P. Sheahan, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science Translational Medicine. 28 Jun 2017:Vol. 9, Issue 396, eaal3653

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (5)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1656823, encodeId=8d57165682350, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Dec 14 10:40:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763318, encodeId=a88c1e633180b, content=<a href='/topic/show?id=1fc5828026' target=_blank style='color:#2F92EE;'>#GS-5734#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8280, encryptionId=1fc5828026, topicName=GS-5734)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fb537484315, createdName=ms5768352621950538, createdTime=Sat Nov 11 08:40:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067249, encodeId=5b36206e249c3, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Jun 01 23:40:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217872, encodeId=7edc21e872ff, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Jul 02 21:55:47 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607773, encodeId=d6a7160e77398, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jul 02 13:40:00 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
2017-12-14 bsmagic9140

#TRA#

32 0
[GetPortalCommentsPageByObjectIdResponse(id=1656823, encodeId=8d57165682350, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Dec 14 10:40:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763318, encodeId=a88c1e633180b, content=<a href='/topic/show?id=1fc5828026' target=_blank style='color:#2F92EE;'>#GS-5734#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8280, encryptionId=1fc5828026, topicName=GS-5734)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fb537484315, createdName=ms5768352621950538, createdTime=Sat Nov 11 08:40:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067249, encodeId=5b36206e249c3, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Jun 01 23:40:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217872, encodeId=7edc21e872ff, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Jul 02 21:55:47 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607773, encodeId=d6a7160e77398, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jul 02 13:40:00 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
2017-11-11 ms5768352621950538

#GS-5734#

28 0
[GetPortalCommentsPageByObjectIdResponse(id=1656823, encodeId=8d57165682350, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Dec 14 10:40:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763318, encodeId=a88c1e633180b, content=<a href='/topic/show?id=1fc5828026' target=_blank style='color:#2F92EE;'>#GS-5734#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8280, encryptionId=1fc5828026, topicName=GS-5734)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fb537484315, createdName=ms5768352621950538, createdTime=Sat Nov 11 08:40:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067249, encodeId=5b36206e249c3, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Jun 01 23:40:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217872, encodeId=7edc21e872ff, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Jul 02 21:55:47 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607773, encodeId=d6a7160e77398, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jul 02 13:40:00 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
2018-06-01 ms3025846204744509

#Transl#

24 0
[GetPortalCommentsPageByObjectIdResponse(id=1656823, encodeId=8d57165682350, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Dec 14 10:40:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763318, encodeId=a88c1e633180b, content=<a href='/topic/show?id=1fc5828026' target=_blank style='color:#2F92EE;'>#GS-5734#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8280, encryptionId=1fc5828026, topicName=GS-5734)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fb537484315, createdName=ms5768352621950538, createdTime=Sat Nov 11 08:40:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067249, encodeId=5b36206e249c3, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Jun 01 23:40:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217872, encodeId=7edc21e872ff, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Jul 02 21:55:47 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607773, encodeId=d6a7160e77398, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jul 02 13:40:00 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
2017-07-02 1dd8c52fm63(暂无匿称)

继续关注

54 0
[GetPortalCommentsPageByObjectIdResponse(id=1656823, encodeId=8d57165682350, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Dec 14 10:40:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763318, encodeId=a88c1e633180b, content=<a href='/topic/show?id=1fc5828026' target=_blank style='color:#2F92EE;'>#GS-5734#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8280, encryptionId=1fc5828026, topicName=GS-5734)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fb537484315, createdName=ms5768352621950538, createdTime=Sat Nov 11 08:40:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067249, encodeId=5b36206e249c3, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Jun 01 23:40:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217872, encodeId=7edc21e872ff, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Jul 02 21:55:47 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607773, encodeId=d6a7160e77398, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jul 02 13:40:00 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
2017-07-02 ms3994565386320060

#Med#

25 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

感染

SCI TRANSL MED：广谱新药GS-5734可有效抵御冠状病毒

相关资讯

科室

工具

服务